1. US Department of Health and Human Services. Guidance for industry. Patient-reported outcome measures: use in medical product development to support labeling claims. 2009. Available at: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM193282.pdf. [Accessed January 14, 2011].
2. US Department of Health and Human Services, Food and Drug Administration. Guidance for industry: qualification process for drug development tools. 2010. Available at: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM230597.pdf. [Accessed January 20, 2012].
3. European Medicines Agency, Committee for Medicinal Products for Human Use. Reflection paper on the regulatory guidance for the use of health related quality of life (HRQL) measures in the evaluation of medicinal products. 2005. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003637.pdf. Accessed August 30, 2013.
4. European Medicines Agency, Committee for Medicinal Products for Human Use. Biomarkers. Available at: http://www.ema.europa.eu/ema/index.jsp?curl=pages/special_topics/general/general_content_000349.jsp&mid=WC0b01ac05800baedb. [Accessed October 19, 2012].
5. Regulatory requirements for trial endpoints in multiregional clinical trials;Girman;Drug Info J,2011